Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) target, is showing promising results in preliminary patient studies. Recent examination implies https://bookmarkpagerank.com/story21407113/retatrutide-emerging-research-and-possible-medical-roles